



2016-05-11

PRESS RELEASE

Clarification of article in BioPharm Insight

Oasmia Pharmaceutical AB is currently, which previously have been communicated, in on-going negotiations with different parties regarding out-licensing of the XR17 platform as well as the company's product candidates, with focus on Paclical[®]/Apealea[®]. In line with past commercial agreements closed by the company, we see future agreements containing both large signing payments in combination with milestone payments when certain events have occurred and an additional royalty component.

It is hard to predict the timing for finalization of agreements.

The company has not had the opportunity to comment on the article before publication.

For more information, please contact:
press@oasmia.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 10.20, CET on May 11, 2016."